Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis, Marsh, R., Dos Santos, C., Yule, A., Dellschaft, N., Hoad, C., Ng, C., Major, G., Smyth, A., Rivett, D., van der Gast, C. 14 May 2024, In: Journal of Cystic Fibrosis
Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome, Marsh, R., Dos Santos, C., Hanson, L., Ng, C., Major, G., Smyth, A., Rivett, D., van der Gast, C. 17 Oct 2023, In: Microbiology spectrum
Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis, Marsh, R., Gavillet, H., Hanson, L., Ng, C., Mitchell-Whyte, M., Major, G., Smyth, A., Rivett, D., van der Gast, C. 1 May 2022, In: Journal of Cystic Fibrosis
